Abstract
Prostate cancer is the leading cause of nonskin malignancy and the second leading cause of cancer death in men. Androgen deprivation therapy is the first-line of systemic therapy against advanced prostate cancer. All advanced prostate cancers eventually grow despite castrate levels of testosterone. We review the evidence that androgen independent prostate cancer continues to require androgen receptor activity for growth, the mechanisms of androgen receptor activation in the castrate setting, and possible points of intervention for novel therapies targeting the androgen receptor and prostate cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 166-170 |
Number of pages | 5 |
Journal | American Journal of Therapeutics |
Volume | 13 |
Issue number | 2 |
DOIs | |
State | Published - Mar 1 2006 |
Keywords
- Androgen receptors
- Genes
- Medical oncology
- Prostatic neoplasms
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)